Cargando…
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a 2-4× increased incidence of death from coronar...
Autores principales: | Saraiva, Francisco Kerr, Sposito, Andrei C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216654/ https://www.ncbi.nlm.nih.gov/pubmed/25338737 http://dx.doi.org/10.1186/s12933-014-0142-7 |
Ejemplares similares
-
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021) -
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in
Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021) -
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
por: Unger, Jeffrey R., et al.
Publicado: (2011) -
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021) -
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)